Reduced-Intensity Conditioning Allogeneic Blood Stem Cell Transplantation with Fludarabine and Oral Busulfan with or without Pharmacokinetically Targeted Busulfan Dosing in Patients with Myeloid Leukemia Ineligible for Conventional Conditioning
Open Access
- 1 June 2005
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 11 (6) , 437-447
- https://doi.org/10.1016/j.bbmt.2005.03.003
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donorsBlood, 2004
- Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effectsBone Marrow Transplantation, 2004
- Busulfan-cyclophosphamide versus total body irradiation–cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: What have we learned?Experimental Hematology, 2003
- HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimenBlood, 2003
- Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosisInternational Journal of Hematology, 2002
- Haematopoietic stem cell transplantation for patients with myelo‐dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)British Journal of Haematology, 2000
- Plasma Concentration Monitoring of BusulfanClinical Pharmacokinetics, 2000
- Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of ageBlood, 2000
- The role of busulfan in bone marrow transplantationMedical Oncology, 1999
- Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients.Journal of Clinical Oncology, 1996